ArticleVeterinary ophthalmology2010
Gene delivery in the equine cornea: a novel therapeutic strategy.
Article in Veterinary ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026Review
- Corneal stromal repair and regeneration.Progress in retinal and eye research · 2022Review
- Novel insights into gene therapy in the cornea.Experimental eye research · 2021Review
- Altering equine corneal fibroblast differentiation through Smad gene transfer.Veterinary ophthalmology · 2018Article
- Single stranded adeno-associated virus achieves efficient gene transfer to anterior segment in the mouse eye.PloS one · 2017Article
- Progress in corneal wound healing.Progress in retinal and eye research · 2015Review
- Corneal gene therapy: basic science and translational perspective.The ocular surface · 2013Review
- Significant inhibition of corneal scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy.Investigative ophthalmology & visual science · 2011Article
- Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo.PloS one · 2011Article
- Vector delivery technique affects gene transfer in the cornea in vivo.Molecular vision · 2010Article
- Efficacy and safety of mitomycin C as an agent to treat corneal scarring in horses using an in vitro model.Veterinary ophthalmology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo determine if hybrid adeno-associated virus serotype 2/5 (AAV5) vector can effectively deliver foreign genes into the equine cornea without causing adverse side effects. The aims of this study were to: (i) evaluate efficacy of AAV5 to deliver therapeutic genes into equine corneal fibroblasts (ECFs) using enhanced green fluorescent protein (EGFP) marker gene, and (ii) establish the safety of AAV5 vector for equine corneal gene therapy. MATERIAL: Primary ECF cultures were harvested from healthy donor equine corneas. Cultures were maintained at 37°C in humidified atmosphere with 5% CO(2). PROCEDURE: AAV5 vector expressing EGFP under control of hybrid cytomegalovirus + chicken β-actin promoter was applied topically to ECF. Expression of delivered EGFP gene in ECF was quantified using fluorescent microscopy. Using fluorescent staining, the total number of cells and transduction efficiency of tested AAV vector was determined. Phase contrast microscopy, trypan blue and TUNEL assays were used to determine toxicity and safety of AAV5 for ECFs.
resultsTopical AAV5 application successfully transduced significant numbers of ECFs. Transduction efficiency was 13.1%. Tested AAV5 vector did not cause phenotype change or significant cell death and cell viability was maintained.
conclusionsTested AAV5 vector is effective and safe for gene therapy in ECFs in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.